Urogen Pharma Stock Price To Sales
| URGN Stock | USD 11.66 0.13 1.13% |
UroGen Pharma fundamentals help investors to digest information that contributes to UroGen Pharma's financial success or failures. It also enables traders to predict the movement of UroGen Stock. The fundamental analysis module provides a way to measure UroGen Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to UroGen Pharma stock.
UroGen |
UroGen Pharma Company Price To Sales Analysis
UroGen Pharma's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current UroGen Pharma Price To Sales | 5.95 X |
Most of UroGen Pharma's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, UroGen Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, UroGen Pharma has a Price To Sales of 5.9455 times. This is 72.22% lower than that of the Biotechnology sector and 93.96% lower than that of the Health Care industry. The price to sales for all United States stocks is 47.94% higher than that of the company.
UroGen Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses UroGen Pharma's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of UroGen Pharma could also be used in its relative valuation, which is a method of valuing UroGen Pharma by comparing valuation metrics of similar companies.UroGen Pharma is currently under evaluation in price to sales category among its peers.
UroGen Fundamentals
| Return On Equity | -14.81 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (1.40) % | ||||
| Operating Margin | (1.08) % | ||||
| Current Valuation | 424.16 M | ||||
| Shares Outstanding | 46.09 M | ||||
| Shares Owned By Insiders | 8.40 % | ||||
| Shares Owned By Institutions | 86.93 % | ||||
| Number Of Shares Shorted | 6.19 M | ||||
| Price To Earning | 239.57 X | ||||
| Price To Book | 19.27 X | ||||
| Price To Sales | 5.95 X | ||||
| Revenue | 90.4 M | ||||
| Gross Profit | 81.52 M | ||||
| EBITDA | (110.33 M) | ||||
| Net Income | (126.87 M) | ||||
| Cash And Equivalents | 111.74 M | ||||
| Cash Per Share | 4.91 X | ||||
| Total Debt | 123.39 M | ||||
| Debt To Equity | 0.44 % | ||||
| Current Ratio | 7.74 X | ||||
| Book Value Per Share | (0.21) X | ||||
| Cash Flow From Operations | (96.77 M) | ||||
| Short Ratio | 17.74 X | ||||
| Earnings Per Share | (2.96) X | ||||
| Target Price | 34.86 | ||||
| Number Of Employees | 235 | ||||
| Beta | 1.13 | ||||
| Market Capitalization | 537.46 M | ||||
| Total Asset | 285.71 M | ||||
| Retained Earnings | (806.22 M) | ||||
| Working Capital | 230.19 M | ||||
| Net Asset | 285.71 M |
About UroGen Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze UroGen Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of UroGen Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of UroGen Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
When determining whether UroGen Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of UroGen Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Urogen Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Urogen Pharma Stock: Check out UroGen Pharma Piotroski F Score and UroGen Pharma Altman Z Score analysis. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.